AbbVie Inc (ABBV)vsFortress Biotech Inc (FBIO)
ABBV
AbbVie Inc
$294.48
-0.18%
HEALTHCARE · Cap: $521.11B
FBIO
Fortress Biotech Inc
$1.99
-1.00%
HEALTHCARE · Cap: $64.37M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 96319% more annual revenue ($66.01B vs $68.47M). FBIO leads profitability with a 163.3% profit margin vs 15.7%. FBIO trades at a lower P/E of 0.7x. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
FBIO
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$294.48
$137.19 premium
Margin of Safety
+73.0%
Fair Value
$13.57
Current Price
$1.99
$11.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 163 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -108.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : FBIO
The strongest argument for FBIO centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 163.3% and operating margin at -53.5%. Revenue growth of 14.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : FBIO
The primary concerns for FBIO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
FBIO carries more volatility with a beta of 1.26 — expect wider price swings.
FBIO is growing revenue faster at 14.0% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (77/100 vs 60/100), backed by strong 15.7% margins and 10.3% revenue growth. FBIO offers better value entry with a 73.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Fortress Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?